Metastatic melanoma is the most aggressive and obstinate skin cancer with poor prognosis.
Variant novel applicable regimens have emerged during the past decades intensively, while …

Simple Summary Malignant melanoma is more dangerous than most other skin cancers due
to its ability to spread early and aggressively. Until the development of new therapeutic …

The incidence of melanoma is increasing worldwide and despite early detection and
intervention, the number of patients dying from metastatic disease continues to rise. The …

Melanoma is the most aggressive and deadly type of skin cancer and is known for its poor
prognosis as soon as metastasis occurs. Since 2011, new and effective therapies for …

Over the past several years, management of advanced melanoma has been transformed by
the development and approval of novel therapeutic approaches. Genetically targeted …

Malignant melanoma is the leading cause of death among cutaneous malignancies. While
its incidence is increasing, the most recent cancer statistics show a small but clear decrease …

Metastatic melanoma remains a lethal disease with a long-term remission rate of less than
10%. Despite many years of research, there has not been a new drug approved in this …

Metastatic melanoma is notorious for its immune evasion and resistance to conventional
chemotherapy. The recent success of ipilimumab, a human monoclonal antibody against …

Simple Summary Immunotherapies and molecularly targeted therapies have drastically
changed the therapeutic approach for unresectable advanced or metastatic melanoma. The …

Simple Summary Immunotherapy has demonstrated the ability to reduce the risk of
recurrence for melanoma following surgical resection and improve survival in patients with …